DEA maintains Schedule I on core psychedelics through 2026; no broad rescheduling.

Predicted 2026-07-16 · Resolves 2026-12-31 · regulatory · USA

74%

ORACLE CONFIDENCE

⏳ Pending

Every outcome is scored publicly in the ledger.

The DEA (the US agency that classifies dangerous drugs) is not expected to move psilocybin, MDMA, or LSD out of their current 'Schedule I' status — the category reserved for substances the government considers highly dangerous with no accepted medical use. This matters because Schedule I status is the main reason these substances are so hard to research, prescribe, or access legally anywhere in the US.

Resolution rule: YES if psilocybin, MDMA, and LSD all remain in Schedule I of the Controlled Substances Act as of 2026-12-31, with no final DEA rescheduling rule published, per federalregister.gov and dea.gov drug-scheduling listings. Any final rule moving any of these three off Schedule I resolves NO. Checked 2026-12-31.

Enforcement priorities will not shift without an approved medical product and airtight diversion controls. DEA has taken no public rescheduling action on core psychedelics.

5 new falsifiable predictions, every day at 12:05 PM ET.

Get tomorrow's Oracle →